logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 9844546 B1

PDFFull Text
Date of Patent:
Dec. 19, 2017

Filed:

May. 15, 2015

Antibody against human hif hydroxylase

Applicant:

Oxford University Innovation Limited, Oxford, GB;

Inventors:

Patrick Henry Maxwell, Oxford, GB;

Christopher William Pugh, Oxford, GB;

Peter John Ratcliffe, Oxford, GB;

Christopher Joseph Schofield, Oxford, GB;

Assignee:

OXFORD UNIVERSITY INNOVATION LIMITED, Oxford, GB;

Attorney:

Finnegan, Henderson, Farabow, Garrett & Dunner, LLP

Primary Examiner:

Bridget E Bunner

Int. Cl.
CPC ...
C07K 16/18 (2006.01); C07K 16/40 (2006.01); C07K 14/47 (2006.01); A61K 31/455 (2006.01); G01N 33/573 (2006.01); C12N 9/02 (2006.01); C12Q 1/26 (2006.01); C07C 235/80 (2006.01); C07C 323/60 (2006.01); C07C 327/32 (2006.01); C07D 213/80 (2006.01); C07D 213/81 (2006.01); C07D 213/82 (2006.01); A61K 31/137 (2006.01); A61K 31/166 (2006.01); A61K 31/185 (2006.01); A61K 31/198 (2006.01); A61K 31/21 (2006.01); A61K 31/225 (2006.01); A61K 31/44 (2006.01); A61K 31/192 (2006.01); A61K 31/195 (2006.01); A61K 31/197 (2006.01); A61K 31/24 (2006.01); A61K 31/327 (2006.01); A61K 31/4412 (2006.01); A61K 31/14 (2006.01); A61K 31/194 (2006.01); A61K 31/221 (2006.01); C07K 14/435 (2006.01); C12N 9/00 (2006.01); A61K 39/395 (2006.01); A61K 38/00 (2006.01);
U.S. Cl.
CPC ...
A61K 31/455 (2013.01); A61K 31/137 (2013.01); A61K 31/14 (2013.01); A61K 31/166 (2013.01); A61K 31/185 (2013.01); A61K 31/192 (2013.01); A61K 31/194 (2013.01); A61K 31/195 (2013.01); A61K 31/197 (2013.01); A61K 31/198 (2013.01); A61K 31/21 (2013.01); A61K 31/221 (2013.01); A61K 31/225 (2013.01); A61K 31/24 (2013.01); A61K 31/327 (2013.01); A61K 31/44 (2013.01); A61K 31/4412 (2013.01); C07C 235/80 (2013.01); C07C 323/60 (2013.01); C07C 327/32 (2013.01); C07D 213/80 (2013.01); C07D 213/81 (2013.01); C07D 213/82 (2013.01); C07K 14/4702 (2013.01); C07K 16/40 (2013.01); C12N 9/0071 (2013.01); C12Q 1/26 (2013.01); G01N 33/573 (2013.01); A01K 2217/05 (2013.01); A61K 38/00 (2013.01); A61K 39/3955 (2013.01); C07K 2317/30 (2013.01); G01N 2333/90245 (2013.01); G01N 2500/04 (2013.01); G01N 2500/20 (2013.01);
Abstract

A novel class of hydroxylases is described having the amino acid sequence of SEQ ID NO: 2, 4, 6 and 8, and variants and fragments thereof having HIF hydroxylation activity. The polypeptides of the invention have in particular prolyl hydroxylase activity. An assay method monitors the interaction of the HIF hydroxylase with a substrate. Modulators of HIF hydroxylase are provided for use in the treatment of a condition associated with increased or decreased HIF levels or activity or for the treatment of a condition where it is desirable to modulate HIF levels or activity.

Find Patent Forward Citations

Loading…